Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study

To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout.The New York Harbor VA computerized patient record system was searched to identify patients with an ICD-9 code for gout meeting at least 4 modified 1977 American Rheumatology Associ...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2020-08, Vol.99 (35), p.e21675-e21675
Main Authors: Slobodnick, Anastasia, Toprover, Michael, Greenberg, Jeffrey, Crittenden, Daria B., Pike, Virginia C., Qian, Yingzhi, Zhong, Hua, Pillinger, Michael H.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Allopurinol - administration & dosage
Allopurinol - therapeutic use
Colchicine - therapeutic use
Diabetes Mellitus, Type 2 - epidemiology
Female
Follow-Up Studies
Gout - drug therapy
Gout Suppressants - administration & dosage
Gout Suppressants - therapeutic use
Humans
Incidence
Male
Medication Adherence
Middle Aged
New York - epidemiology
Observational Study
Retrospective Studies
Time Factors
United States - epidemiology
United States Department of Veterans Affairs
Uric Acid - blood
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout.The New York Harbor VA computerized patient record system was searched to identify patients with an ICD-9 code for gout meeting at least 4 modified 1977 American Rheumatology Association gout diagnostic criteria. Patients were divided into subgroups based on >30 continuous days of allopurinol, versus no allopurinol. New diagnoses of diabetes, defined according to American Diabetes Association diagnostic criteria or clinical documentation explicitly stating a new diagnosis of diabetes, were identified during an observation period from January 1, 2000 through December 31, 2015.Six hundred six gout patients used allopurinol >30 continuous days, and 478 patients never used allopurinol. Over an average 7.9 ± 4.8 years of follow-up, there was no significant difference in diabetes incidence between the allopurinol and non-allopurinol groups (11.7/1000 person-years vs 10.0/1000 person-years, P = .27). A lower diabetes incidence in the longest versus shortest quartiles of allopurinol use (6.3 per 1000 person-years vs 19.4 per 1000 person-years, P
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000021675